The Role of Congenital Cytomegalovirus Infection in Adverse Birth Outcomes: A Review of the Potential Mechanisms.


Journal

Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722

Informations de publication

Date de publication:
24 12 2020
Historique:
received: 20 11 2020
revised: 14 12 2020
accepted: 21 12 2020
entrez: 30 12 2020
pubmed: 31 12 2020
medline: 24 2 2021
Statut: epublish

Résumé

Human cytomegalovirus (CMV) is a major cause of nonhereditary adverse birth outcomes, including hearing and visual loss, neurologic deficits, and intrauterine growth retardation (IUGR), and may contribute to outcomes such as stillbirth and preterm delivery. However, the mechanisms by which CMV could cause adverse birth outcomes are not fully understood. This study reviewed proposed mechanisms underlying the role of CMV in stillbirth, preterm birth, and IUGR. Targeted literature searches were performed in PubMed and Embase to identify relevant articles. Several potential mechanisms were identified from in vitro studies in which laboratory-adapted and low-passage strains of CMV and various human placental models were used. Potential mechanisms identified included impairment of trophoblast progenitor stem cell differentiation and function, impairment of extravillous trophoblast invasiveness, dysregulation of Wnt signaling pathways in cytotrophoblasts, tumor necrosis factor-α mediated apoptosis of trophoblasts, CMV-induced cytokine changes in the placenta, inhibition of indoleamine 2,3-dioxygenase activity, and downregulation of trophoblast class I major histocompatibility complex molecules. Inherent challenges for the field remain in the identification of suitable in vivo animal models. Nonetheless, we believe that our review provides useful insights into the mechanisms by which CMV impairs placental development and function and how these changes could result in adverse birth outcomes.

Identifiants

pubmed: 33374185
pii: v13010020
doi: 10.3390/v13010020
pmc: PMC7823935
pii:
doi:

Substances chimiques

Biomarkers 0

Types de publication

Journal Article Meta-Analysis Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Références

J Virol. 2000 Aug;74(15):6808-20
pubmed: 10888620
Fetal Diagn Ther. 2013;33(4):203-14
pubmed: 23571413
Front Microbiol. 2014 May 19;5:218
pubmed: 24904534
Pediatrics. 2014 Nov;134(5):972-82
pubmed: 25349318
Curr Pharm Biotechnol. 2011 May;12(5):814-23
pubmed: 21342117
Front Genet. 2013 Sep 26;4:190
pubmed: 24133501
Am J Obstet Gynecol. 2020 Sep;223(3):330-349
pubmed: 32105678
Arch Pathol Lab Med. 2019 May;143(5):639-642
pubmed: 30500287
Viruses. 2014 Mar 19;6(3):1346-64
pubmed: 24651029
Placenta. 2010 Oct;31(10):839-47
pubmed: 20716463
Am J Reprod Immunol. 2013 Apr;69(4):395-407
pubmed: 23432707
J Virol. 2015 Nov 11;90(2):1108-15
pubmed: 26559837
Placenta. 2017 Nov;59 Suppl 1:S8-S16
pubmed: 28477968
PLoS One. 2012;7(12):e52899
pubmed: 23300810
PLoS Pathog. 2012;8(10):e1002959
pubmed: 23071438
J Virol. 2010 Mar;84(6):2946-54
pubmed: 20042507
J Infect Dis. 2014 May 15;209(10):1573-84
pubmed: 24403553
J Pathol. 2006 Sep;210(1):111-20
pubmed: 16826536
Mediators Inflamm. 2014;2014:579279
pubmed: 24812442
Organogenesis. 2008 Apr;4(2):68-75
pubmed: 19279717
Biol Reprod. 2016 Nov;95(5):113
pubmed: 27733378
Front Immunol. 2019 Jun 10;10:1155
pubmed: 31244824
Dev Biol. 2004 Jul 1;271(1):26-37
pubmed: 15196947
Front Immunol. 2018 Dec 06;9:2880
pubmed: 30574149
Rev Med Virol. 2010 Jul;20(4):202-13
pubmed: 20564615
Placenta. 2009 Nov;30(11):994-1001
pubmed: 19796811
Rev Med Virol. 2019 May;29(3):e2034
pubmed: 30706584
Placenta. 2011 Jul;32(7):522-30
pubmed: 21605903
J Virol. 2015 May;89(9):5134-47
pubmed: 25741001
Med Microbiol Immunol. 2015 Jun;204(3):273-84
pubmed: 25894764
Curr Opin Virol. 2017 Aug;25:126-133
pubmed: 28888133
ILAR J. 2006;47(1):49-64
pubmed: 16391431
PLoS One. 2015 Jul 14;10(7):e0132627
pubmed: 26171612
Front Pediatr. 2020 Jan 31;8:13
pubmed: 32083040
Am J Pathol. 2002 Oct;161(4):1371-81
pubmed: 12368210
Virol J. 2011 Mar 11;8:114
pubmed: 21392403
J Virol. 2011 Dec;85(24):13204-13
pubmed: 21976654
J Infect Dis. 2018 Sep 22;218(9):1464-1473
pubmed: 29860306
FEMS Microbiol Rev. 2018 Mar 1;42(2):137-145
pubmed: 29361041
Curr Top Microbiol Immunol. 2008;325:383-95
pubmed: 18637517
J Clin Microbiol. 2017 Mar;55(3):693-702
pubmed: 28031434
Nature. 2019 Jun;570(7760):148
pubmed: 31186554
Trends Microbiol. 2005 Apr;13(4):164-74
pubmed: 15817386
Semin Immunopathol. 2014 Nov;36(6):615-25
pubmed: 25291972
Rev Med Virol. 2007 Jul-Aug;17(4):253-76
pubmed: 17579921
J Virol. 2004 Mar;78(6):2831-40
pubmed: 14990702
J Immunol. 2000 Jan 15;164(2):805-11
pubmed: 10623826

Auteurs

Annete Njue (A)

RTI Health Solutions, Manchester M20 2LS, UK.

Carolyn Coyne (C)

Department of Pediatrics, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA.

Andrea V Margulis (AV)

RTI Health Solutions, 08028 Barcelona, Spain.

Dai Wang (D)

Merck & Co., Inc., Kenilworth, NJ 07033, USA.

Morgan A Marks (MA)

Merck & Co., Inc., Kenilworth, NJ 07033, USA.

Kevin Russell (K)

Merck & Co., Inc., Kenilworth, NJ 07033, USA.

Rituparna Das (R)

Merck & Co., Inc., Kenilworth, NJ 07033, USA.

Anushua Sinha (A)

Merck & Co., Inc., Kenilworth, NJ 07033, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH